Next Article in Journal
Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea–Japan Study
Previous Article in Journal
Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
Open AccessReview

K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review

1
Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA
2
Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(3), 447; https://doi.org/10.3390/cancers13030447
Received: 4 December 2020 / Revised: 11 January 2021 / Accepted: 21 January 2021 / Published: 25 January 2021
(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
The cancer associated protein BRCA2 is the subject of intense continual study. Because of this, new insights into the relation of specific variants of this gene and cancer are regularly generated. These discoveries shed light on cancer risk and management for patients carrying these mutations. Additionally, new techniques for variant discovery and investigation are developed and tested, further enhancing scientific and clinical understanding of this key protein. In this review we will investigate the recent literature associated with variants in the C-terminus of BRCA2 and their effect on health and cancer predisposition.
Whole genome analysis and the search for mutations in germline and tumor DNAs is becoming a major tool in the evaluation of risk as well as the management of hereditary cancer syndromes. Because of the identification of cancer predisposition gene panels, thousands of such variants have been catalogued yet many remain unclassified, presenting a clinical challenge for the management of hereditary cancer syndromes. Although algorithms exist to estimate the likelihood of a variant being deleterious, these tools are rarely used for clinical decision-making. Here, we review the progress in classifying K3326X, a rare truncating variant on the C-terminus of BRCA2 and review recent literature on other novel single nucleotide polymorphisms, SNPs, on the C-terminus of the protein, defined in this review as the portion after the final BRC repeat (amino acids 2058–3418). View Full-Text
Keywords: hereditary breast and ovarian cancer syndrome; HBOC; hereditary breast ovarian and pancreatic cancer syndrome; HBOPC; BRCA2; K33326X hereditary breast and ovarian cancer syndrome; HBOC; hereditary breast ovarian and pancreatic cancer syndrome; HBOPC; BRCA2; K33326X
Show Figures

Figure 1

MDPI and ACS Style

Baughan, S.; Tainsky, M.A. K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review. Cancers 2021, 13, 447. https://doi.org/10.3390/cancers13030447

AMA Style

Baughan S, Tainsky MA. K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review. Cancers. 2021; 13(3):447. https://doi.org/10.3390/cancers13030447

Chicago/Turabian Style

Baughan, Scott; Tainsky, Michael A. 2021. "K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review" Cancers 13, no. 3: 447. https://doi.org/10.3390/cancers13030447

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop